Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Emir Hadzijusufovic, DVM, Gregor Hoermann, MD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Bernd Jilma, MD, Gerit H. Schernthaner, MD, Peter Valent, MD

Blood (2017) 130 (Supplement 1): 1619.

https://doi.org/10.1182/blood.V130.Suppl_1.1619.1619

Published: 2017

Journal Articles

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Bernd Jilma, MD, James C Gilbert, MD, Sandip Panicker, PhD, Graham C Parry, PhD, Michael Fillitz, MD, Schenk Thomas, Christian Sillaber, MD, Johann Bartko, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 2435.

https://doi.org/10.1182/blood.V128.22.2435.2435

Published: 2016

Journal Articles

Natural IgM Against Oxidation-Specific Epitopes Inhibit Microvesicle-Driven Coagulation

Georg Obermayer, MD, Taras Afonyushkin, PhD, Florian Puhm, MSc, Michael Schwameis, MD, Bernd Jilma, MD, Christoph J Binder, MD PhD

Blood (2016) 128 (22): 2562.

https://doi.org/10.1182/blood.V128.22.2562.2562

Published: 2016

Journal Articles

Highly Procoagulant Extracellular Vesicles in Amniotic Fluid

Johannes Thaler, MDPhD, Lena Hell, MSc, Lukas Wisgrill, MD, Andreas Spittler, MD, Michael Schwameis, MD, Bernd Jilma, MD, Peter Altevogt, MD, Cihan Ay, MD, Ingrid Pabinger, MD

Blood (2016) 128 (22): 4961.

https://doi.org/10.1182/blood.V128.22.4961.4961

Published: 2016

Journal Articles

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Sandip Panicker, PhD, Christa Drucker, Sami Hussain, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 94.

https://doi.org/10.1182/blood.V128.22.94.94

Published: 2016

Journal Articles

Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia

Lukas Kazianka, Christa Drucker, Cathrin Skrabs, MD, Philipp Bernhard Staber, MD PhD, Edit Anna Porpaczy, MD PhD, Christine Einberger, Marion Heinz, Alexander Hauswirth, MD, Ingrid Pabinger, MD, Peter Quehenberger, MD, Bernd Jilma, MD, Ulrich Jaeger, MD

Blood (2015) 126 (23): 718.

https://doi.org/10.1182/blood.V126.23.718.718

Published: 2015

Journal Articles

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

Ulrich Jaeger, MD, Eileen L Rose, Andrew Singh, Sebastian H A Feickert, Simon Panzer, Bernd Jilma, MD, James C. Gilbert, MD, Sandip Panicker, PhD

Blood (2015) 126 (23): 3560.

https://doi.org/10.1182/blood.V126.23.3560.3560

Published: 2015

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices Is Adamts-13 Dependent

Petra Jilma-Stohlawetz, MD, Schima Heinrich, PhD, Martin Stoiber, Peter Quehenberger, MD, Sabine Schranz, RN, Bernd Jilma, MD

Blood (2013) 122 (21): 3602.

https://doi.org/10.1182/blood.V122.21.3602.3602

Published: 2013

Journal Articles

Reversal Strategy For Antagonizing The P2Y12-Inhibitor Ticagrelor By Platelet Concentrates

Hobl Eva-Luise, PhD, Petra Jilma-Stohlawetz, MD, Ulla Derhaschnig, MD, Schoergenhofer Christian, MD, Michael Schwameis, MD, Bernd Jilma, MD

Blood (2013) 122 (21): 1153.

https://doi.org/10.1182/blood.V122.21.1153.1153

Published: 2013

Journal Articles

Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,

Petra Jilma-Stohlawetz, MD, Paul Knoebl, MD, Ingrid Pabinger, MD, James Gilbert, MD, Robert G. Schaub, PhD, Bernd Jilma, MD

Blood (2011) 118 (21): 3377.

https://doi.org/10.1182/blood.V118.21.3377.3377

Published: 2011

Journal Articles

Effects of Strong P2Y12 Receptor Inhibition by Prasugrel on Platelet Inhibition During Endotoxemia: A Randomized Controlled Trial

Alexander O Spiel, MD, Ulla Derhaschnig, MD, Petra Jilma-Stohlawetz, MD, Bernd Jilma, MD

Blood (2011) 118 (21): 1245.

https://doi.org/10.1182/blood.V118.21.1245.1245

Published: 2011

Journal Articles

Strong Correlation of High Endogenous Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) with Poor Blood Clotting and Corrective Action of BAX 513 Under FVIII-Inhibited Conditions

Michael Dockal, PhD, Monika Gorczyca, PhD, Sabine Knappe, PhD, Michael Palige, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Bernd Jilma, MD

Blood (2011) 118 (21): 1201.

https://doi.org/10.1182/blood.V118.21.1201.1201

Published: 2011

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Spero R Cataland, MD, Flora Peyvandi, MD, PhD, Pier M. Mannucci, MD, Bernhard Lämmle, Johanna A Kremer Hovinga, MD, Samuel J Machin, Marie Scully, Gail Rock, PhD, MD, FRCP, James Gilbert, MD, Paul Knoebl, Shangbin Yang, PhD, Haifeng Wu, M.D., Bernd Jilma, MD

Blood (2010) 116 (21): 726.

https://doi.org/10.1182/blood.V116.21.726.726

Published: 2010

Journal Articles

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Petra Paulinska, MD, Bernd Jilma, MD, Christa Firbas, MD, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 3374.

https://doi.org/10.1182/blood.V112.11.3374.3374

Published: 2008

Journal Articles

Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome.

Paul Knoebl, Silvia Koder, Peter Schellongowski, Peter Distelmaier, Peter Quehenberger, Ingrid Pabinger, Bernd Jilma, MD

Blood (2008) 112 (11): 2291.

https://doi.org/10.1182/blood.V112.11.2291.2291

Published: 2008

Journal Articles

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

Chri sta Firbas, MD, Bernd Jilma, MD, Patricia G Wagner, Renta Hutabarat, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 2298.

https://doi.org/10.1182/blood.V112.11.2298.2298

Published: 2008

Journal Articles

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Jilma, MD, Florian B. Mayr, MD, Paul Knoebl, MD, Alexander O. Spiel, MD, Patricia G. Merlino, Robert Schaub, PhD, James C. Gilbert, MD

Blood (2007) 110 (11): 279.

https://doi.org/10.1182/blood.V110.11.279.279

Published: 2007

Journal Articles

Functional Role of the Chemokine Binding Duffy Antigen Receptor Complex (DARC) in Human Inflammation In Vivo.

Florian B. Mayr, MD, Petra Jilma-Stohlawetz, MD, Christa Firbas, MD, Anthony F. Suffredini, MD, Hartmut Derendorf, MD, Bernd Jilma, MD

Blood (2006) 108 (11): 20.

https://doi.org/10.1182/blood.V108.11.20.20

Published: 2006

NARROW

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Natural IgM Against Oxidation-Specific Epitopes Inhibit Microvesicle-Driven Coagulation

Highly Procoagulant Extracellular Vesicles in Amniotic Fluid

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices Is Adamts-13 Dependent

Reversal Strategy For Antagonizing The P2Y12-Inhibitor Ticagrelor By Platelet Concentrates

Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,

Effects of Strong P2Y12 Receptor Inhibition by Prasugrel on Platelet Inhibition During Endotoxemia: A Randomized Controlled Trial

Strong Correlation of High Endogenous Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) with Poor Blood Clotting and Corrective Action of BAX 513 Under FVIII-Inhibited Conditions

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome.

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Functional Role of the Chemokine Binding Duffy Antigen Receptor Complex (DARC) in Human Inflammation In Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only